title: Differential effects of atropine and a cholecystokinin receptor antagonist on pancreatic secretion.
abstract: The present study evaluates the effect of atropine and of the cholecystokinin receptor antagonist loxiglumide on feedback regulation of basal pancreatic secretion in 6 healthy volunteers. The intraduodenal instillation of the protease inhibitor camostate reduced enzymatic activities of trypsin and chymotrypsin by 80%. This was accompanied by a strong increase in amylase and lipase output. The intravenous infusion of atropine (5 micrograms/kg.h) completely abolished the stimulatory effect of camostate on enzyme output. The infusion of loxiglumide (10 mg/kg.h) caused no changes in camostate-induced stimulation of enzyme output. Plasma levels of cholecystokinin were not altered after intraduodenal instillation of camostate whether atropine, loxiglumide, or saline were infused. We suggest that the protease inhibitor camostate, by inhibition of the enzymatic activity of trypsin and chymotrypsin, interferes with feedback regulation of basal pancreatic secretion in humans, and this mechanism is predominantly mediated by the cholinergic system.
authors.affiliation: Department of Internal Medicine, University of Marburg, Federal Republic of Germany.
authors.forename: G
authors.initials: G
authors.lastname: Adler
authors.forename: M
authors.initials: M
authors.lastname: Reinshagen
authors.forename: I
authors.initials: I
authors.lastname: Koop
authors.forename: B
authors.initials: B
authors.lastname: Göke
authors.forename: A
authors.initials: A
authors.lastname: Schafmayer
authors.forename: L C
authors.initials: LC
authors.lastname: Rovati
authors.forename: R
authors.initials: R
authors.lastname: Arnold
mesh_terms: D000328:Adult; D001285:Atropine / Q000494:pharmacology*; D002766:Cholecystokinin / Q000037:antagonists & inhibitors* / Q000097:blood / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D004952:Esters; D005246:Feedback; D016670:Gabexate / Q000031:analogs & derivatives*; D005973:Glutamine / Q000031:analogs & derivatives*; D006146:Guanidines / Q000494:pharmacology; D006801:Humans; D008297:Male; D010179:Pancreas / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism; D010447:Peptide Hydrolases / Q000378:metabolism; D011377:Proglumide / Q000031:analogs & derivatives* / Q000494:pharmacology; D011480:Protease Inhibitors / Q000494:pharmacology; D011674:Pulse / Q000187:drug effects; D012016:Reference Values
chemical_list: D004952:Esters; D006146:Guanidines; D011480:Protease Inhibitors; C034532:camostat; D005973:Glutamine; D016670:Gabexate; C053737:loxiglumide; D001285:Atropine; D002766:Cholecystokinin; D010447:Peptide Hydrolases; D011377:Proglumide